唑来膦酸对社区诊所骨密度及骨转换标志物的影响。

Effect of zoledronic acid on bone density and markers of bone turnover in a community clinic.

作者信息

Lim Ria, Zailskas Susan, Goldsby Tashauna U, Lukens Carrie, Muravev Rostislav, Dulipsingh Latha

机构信息

Endocrinology and Bone Health Center, The Hospital of Central Connecticut, New Britain, USA.

出版信息

Conn Med. 2013 Jun-Jul;77(6):357-9.

PMID:23923255

Abstract

OBJECTIVE

This study aims to document the efficacy of zoledronic acid by comparing bone densities and markers of bone turnover, in patients with osteoporosis.

METHODS

Bone mineral density (BMD) and urinary N-telopeptide, a marker of bone turnover, were compared before and after treatment with intravenous zoledronic acid.

RESULTS

52 participants had atleast two doses of zoledronic acid over 36 months. Significant increases in BMD were found in the spine (t=4.38, P<0.01) and decrease in bone turnover marker N-telopeptide (t=3.30, P=0.002). Small but significant correlations were determined between prior steroid use and change in BMD in the spine (r=0.35, P<0.05), and family history of osteoporosis and change in BMD in the right femur (r=0.38, P<0.05).

CONCLUSION

Annual infusions of zoledronic acid for at least two years, revealed a significant increase in bone density at the spine and a decrease in urinary N-telopeptide in patients treated at our center.

摘要

目的

本研究旨在通过比较骨质疏松症患者的骨密度和骨转换标志物，来记录唑来膦酸的疗效。

方法

比较静脉注射唑来膦酸治疗前后的骨矿物质密度（BMD）和骨转换标志物尿N-端肽。

结果

52名参与者在36个月内至少接受了两剂唑来膦酸治疗。脊柱骨密度显著增加（t = 4.38，P < 0.01），骨转换标志物N-端肽降低（t = 3.30，P = 0.002）。既往使用类固醇与脊柱骨密度变化之间存在小但显著的相关性（r = 0.35，P < 0.05），骨质疏松家族史与右股骨骨密度变化之间也存在相关性（r = 0.38，P < 0.05）。